Results: Vitamin D3 was titrated to 1000 IU/day in 15/26 (58%), to 2000 IU/day in 10 and 3000 IU/day in one. D3 had no effect on cholesterol or cholesterol subfractions except for decreases in atorvastatin-treated patients (cholesterol, p=.08; LDL-cholesterol, p=.05). Decreased campesterol concentrations (p=.05) were seen with D3 but not placebo in statin-treated patients. Relationships between total 25-OH D and lipids were not detected, but, inverse linear relationships were detected between free25-OH D and triglycerides (p=.03 for all participants (n=49), p=.03 in all statin-treated (n=19) and p=.0009 in atorvastatin-treated (n=11), and between free 25-OH D and LDL-cholesterol (p=.08 overall, p=.02 in all statin-treated and p=.03 for atorvastatin-treated), and total cholesterol (p= .09 overall; p=.04 for all statin-treated and p=.05 for atorvastatin-treated). 
INTRODUCTION

1
A role for vitamin D in the atherosclerotic process has been hypothesized as serum vitamin D 2 levels have been inversely correlated with the degree of coronary artery calcification as determined by 3 cardiac computed tomography, prevalence of hypertension, diabetes, obesity, high serum triglyceride 4 levels, and cardiovascular and overall mortality. [1] [2] [3] [4] The underlying mechanism of such benefits has 5 not been established.
6
We previously investigated the effects of oral vitamin D supplementation (800 IU /day: 400 IU 7 D3 and 400 IU D2 as part of multivitamins and combined with calcium) in patients receiving 8
atorvastatin in an open label cross-over study. [5] Although not an entry criteria for our study, most 9 participants were vitamin D deficient in the absence of supplementation. We hypothesized that 
16
Strong cross-sectional associations between higher 25-OH vitamin D levels and lower total 17 cholesterol, lower LDL cholesterol, higher HDL cholesterol and lower triglycerides have been reported 18 from a large community database with a longitudinal analysis that showed increasing 25-OH D levels 19 affected total and HDL-cholesterol levels but not LDL-cholesterol and triglyceride levels. [6] 
20
Prospective data on effects of vitamin D on lipids are limited with differing results in those that have 21 been reported. [7] [8] [9] [10] [11] [12] [13] [14] Vitamin D has been reported to lower triglyceride levels and to a lesser extent 22 cholesterol concentrations as well as having no effect on these measures in small studies that largely 23 lacked blinding or placebo groups. [7] [8] [9] [10] [11] [12] [13] [14] The studies used relatively low doses of oral vitamin D3
24
(300-1000 IU/day), oral 1a,25-(OH) 2 vitamin D or i.v. 1a, 
98
[21 ]
99
Total plasma cholesterol precursor lathosterol and the plant sterol campesterolwere were determined by gas 100 chromatography-mass spectrometry-selected ion monitoring (GC-MS-SIM) using epicoprostanol as internal 101 standard. Cholesterol was measured from the same plasma sample by GC-flame ionization detection (GC-102 FID) using 5-cholestane as internal standard. [22, 23] 
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Adherence was determined from pill counts o. 
124
Subjects. Fifty-six subjects had total 25-OH D levels <25 ng/mL on initial screening with two 125 ineligible due to 25-OH D concentrations > 25 ngl/mL on repeat baseline measurement. Fifty-four 126 subjects underwent randomization stratified by sex and season; there was one subject dropout due to 127 physical relocation and four were removed due to study non-adherence (sunburn at visits, stated non-128 adherence with capsule intake, stated significant change in diet). Data were analyzed for forty-nine 
160
(f 16.7 ±4.4 ng/mL at entry and 17.9 ±8.3 at study end). Free 25-OH vitamin D levels at baseline ranged 161 from 1.7 to 4.5 pg/mL and undetectable in one participant. Free 25-OH levels increased with D3 to a 162 mean of 5.7 ±1.1 pg/mL (p<.0001; range 1.6 to 7.9 pg/mL) at study end and were unchanged with 163 placebo (see Table 2 ). 25-OH vitamin D2 levels were detectable in 4 subjects at baseline (3 assigned to 164 D3 and 1 assigned to placebo) and two at study end (both assigned to placebo). 
182
The decrease in the ratio of campesterol to cholesterol in the D3 treated compared to placebo did not 
206
Safety measures. Calcium concentrations did not change with D3 or placebo ( 
211
Vital Signs. Weight and heart rate were unchanged during the study. Systolic and blood pressure 212 decreased slightly but significantly (p<.04) for both the placebo and vitamin D group; from 128 ± 21 213 mmHg to 123 ± 15 after 6 weeks and 124.8 ±22 mmHg in the D3 group and from 125 ±15 mmHg to 214 118 ±14 after 6 weeks and 124 ± 17 mmHg after 12 weeks in the placebo group.
215
Adherence. Mean adherence was 98 ±6 % in the vitamin D3 group and 97 ±7% in the placebo group.
217
DISCUSSION
219
Vitamin D plays a role in the regulation of hundreds of genes involved in bone and mineral 220 metabolism, the renin-angiotensin-aldosterone system, the immunologic system, the cardiovascular 
234
We detected no effect of vitamin D3 supplementation and increased total circulating 25-OH 
253
In humans, while statins inhibit cholesterol synthesis they also upregulate cholesterol 254 absorption. [30, 31] Cholesterol balance studies of cholesterol synthesis and intestinal 255 cholesterol absorption have demonstrated that the plasma sterol campesterol can serve as a 256 marker of fractional cholesterol absorption and the plasma sterol lathosterol as a surrogate 257 serum marker of endogenous whole body cholesterol biosynthesis.
[32] We found campesterol 258 concentrations decreased in statin-treated participants after vitamin D3 administration 259 compared to statin-treated participants receiving placebo that had no changes in campesterol 260 concentrations. Furthermore, no effect of vitamin D3 administration on campesterol 261 concentrations was seen in non-statin treated participants. We also failed to find any effect of 262 vitamin D3 on lathosterol concentrations compared to placebo administration. The lack of 263 changes in lathosterol argue against a decrease in cholesterol synthesis either by direct effects or due to 
304
In summary, our data support the existence of an interaction of vitamin D3 with lipids in HMG
305
CoA reductase (stain) treated patients in directions that would be clinically favorable and that a 306 contributing underlying mechanism is likely to be reduced cholesterol absorption. Free 25-OH Vitamin D3 (pg/mL) Vitamin D3 Group 2.9 ± 0.9 4.7 ± 1.1 5.7 ±1.1 p <.0001
Placebo Group 2.9 ± 0.7 3.2 ± 0. Figure: Final Fig 2.ppt 
